GS
CRNX icon

GTS Securities’s Crinetics Pharmaceuticals CRNX Stock Holding History

GTS Securities’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,000
Closed -$249K – 3934
2023
Q4 		$249K Sell
7,000
-38,200
-85% -$1.17M ﹤0.01% 3379
2023
Q3 		$1.34M Buy
+45,200
New +$931K ﹤0.01% 1791

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GTS Securities's CRNX Position: Q4 2023 in Review

GTS Securities sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 13,874 shares — an estimated $425K sold.

GTS Securities first reported a position in CRNX in Q3 2023 and held it in 1 quarter. The position peaked at $413K in Q3 2023. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

  • GTS Securities reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • GTS Securities sold 13,874 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $425K.
  • GTS Securities first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • GTS Securities's Crinetics Pharmaceuticals position peaked at $413K in Q3 2023.
  • 181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.